Some of my most satisfying moments as a clinician over the past 50 years have been when I conducted in vivo behavior therapy exposure and practice with patients suffering from anxiety and phobias.
Gilead is soaring to new heights in the CAR-T therapeutics sector, acquiring in vivo cell therapy specialist Interius BioTherapeutics via its subsidiary Kite for $350m. The deal will integrate ...
In vivo CAR T-cell therapies promise to revolutionize cancer treatment, enhancing access and reducing costs while addressing financial toxicity and logistical barriers. During her honeymoon in Papua ...
Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial ...
Precision BioSciences’ most advanced cell therapy for a type of blood cancer is on track for a pivotal clinical trial, but that study is no longer its responsibility. The biotech is outlicensing ...
If Editas Medicine’s CRISPR gene-editing therapy for rare blood diseases reaches the market, it will be in the hands of a different company. The biotech on Tuesday announced plans to partner or ...
Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback